Pyoderma Gangrenosum Following Mycobacterium Indicus pranii Vaccination for COVID-19 Infection
Saved in:
Main Authors: | Sukhdeep Singh (Author), Shikha Shah (Author), Tarun Narang (Author), Debajyoti Chatterjee (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mycobacterium indicus pranii (MIP) vaccine: Pharmacology, indication, dosing schedules, administration, and side effects in clinical practice
by: Sunil Dogra, et al.
Published: (2023) -
Mycobacterium indicus pranii vaccination-induced cutaneous granuloma in COVID-19 patients
by: Yapamakula Anisha Amarnath, et al.
Published: (2023) -
Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine
by: Sunil Kumar Gupta, et al.
Published: (2022) -
Persistent exaggerated granulomatous hypersensitivity reaction to Mycobacterium indicus pranii immunomodulatory therapy for COVID-19 sepsis
by: Nikhil Mehta, et al.
Published: (2023) -
Pyoderma gangrenosum following COVID-19 infection
by: Khezar Syed, et al.
Published: (2021)